Higher Risk Myelodysplastic Syndromes clinical trials

Explore recruiting higher risk myelodysplastic syndromes clinical trials.

Recruiting higher risk myelodysplastic syndromes studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Higher Risk Myelodysplastic Syndromes trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Prospective randomized study on the feasibility of allogeneic stem cell transplantation in higher-risk-myelodysplastic syndromes, performed upfront or preceded by azacitidine or conventional chemotherapy, according to the BM-blast proportion (ACROBAT trial). MDS0519

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

GFM-ONUVEN-MDS : A phase I/II, open-label, single arm, multicenter dose-finding study to assess the safety and preliminary efficacy of Oral Azacitidine CC-486 (ONUREG®) in combination with Venetoclax (VENCLYXTO®) in previously untreated higher-risk myelodysplastic syndromes ineligible for allogenic transplantation

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Germany, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

France, Spain, Germany, Denmark, Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Higher Risk Myelodysplastic Syndromes trials by city

Higher Risk Myelodysplastic Syndromes in Toronto Higher Risk Myelodysplastic Syndromes in Vancouver Higher Risk Myelodysplastic Syndromes in Montreal Higher Risk Myelodysplastic Syndromes in Calgary Higher Risk Myelodysplastic Syndromes in Edmonton Higher Risk Myelodysplastic Syndromes in Ottawa Higher Risk Myelodysplastic Syndromes in Winnipeg Higher Risk Myelodysplastic Syndromes in Quebec City Higher Risk Myelodysplastic Syndromes in Hamilton Higher Risk Myelodysplastic Syndromes in Kitchener Higher Risk Myelodysplastic Syndromes in London Higher Risk Myelodysplastic Syndromes in Halifax Higher Risk Myelodysplastic Syndromes in New York Higher Risk Myelodysplastic Syndromes in Los Angeles Higher Risk Myelodysplastic Syndromes in Chicago Higher Risk Myelodysplastic Syndromes in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease